Vitamin A and some of its analogs (retinoids) prevent squamous differentiation of normal nonkeratinizing epithelial cells in vivo and in vitro and suppress oral premalignant lesions (leukoplakia) in man and carcinogenesis in the upper aerodigestive tract in experimental animals. The mechanism(s) by which retinoids exert these effects is not known. Nuclear retinoic acid receptors (RARs) function as ligand-activated trans-acting transcription modulating factors and mediate the effects of retinoids on the expression of certain genes. The hypotheses underlying this project are: (A) Retinoids' ability to suppress malignant cells, and (B) These effects result from changes in gene expression mediated via nuclear retinoid receptors. The objectives of this project are: To determine the relevance of the RARs for mediation of the effects of retinoids on the growth and differentiation of human head and neck squamous cell carcinoma (HNSCC) cells in vitro. Three HNSCC cell lines before and during treatment with 13-cis retinoic acid (13cRA) in vitro and biopsies of human oral mucosa and leukoplakia lesions taken from patients before and during treatment with 13cRA will be used to: (a) Determine the presence and level of RAR-alpha, RAR-beta, RAR-gamma, and RXR-alpha in HNSCC cells at the mRNA level (by Northern blotting) and at the protein level (by immunoblotting and radioactive retinoid binding); (b) Determine whether the expression of any of the RARs is modulated in HNSCC cells by retinoid treatment; (c) Determine whether the level of any of the RARs before and after retinoid treatment is related to the responsiveness of the HNSCC cells to the effects of 13cRA on squamous cell differentiation markers transglutaminase, involucrin, and K1 keratin at the mRNA level and at the protein level; (d) Determine whether blocking the expression of one or more of the RARs by antisense oligonucleotides or mRNA will inhibit any of the effects of 13cRA on the HNSCC cells; (e) Determine the presence and level of RARs and the expression of transglutaminase, involucrin, and K1 keratin in """"""""normal"""""""" mucosa cells and in biopsies from oral leukoplakia lesions before and after treatment with 13cRA in vivo by in situ hybridization with nucleotide probes for RARs' and differentiation markers' mRNAs, and immunohistochemical analysis with antibodies to each receptor and differentiation marker. These studies are expected to provide important information on the involvement of RARs in the mechanism of action of retinoids on HNSCC in vitro and possibly on premalignant oral epithelial cells in vivo.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA052051-10
Application #
6418166
Study Section
Project Start
2001-02-05
Project End
2002-11-30
Budget Start
Budget End
Support Year
10
Fiscal Year
2001
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
001910777
City
Houston
State
TX
Country
United States
Zip Code
77030
Hildebrandt, Michelle A T; Lippman, Scott M; Etzel, Carol J et al. (2012) Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict head and neck cancer patient second primary tumor/recurrence risk and response to retinoid chemoprevention. Clin Cancer Res 18:3705-13
Lee, J Jack; Wu, Xifeng; Hildebrandt, Michelle A T et al. (2011) Global assessment of genetic variation influencing response to retinoid chemoprevention in head and neck cancer patients. Cancer Prev Res (Phila) 4:185-93
Wang, Jianming; Lippman, Scott M; Lee, J Jack et al. (2010) Genetic variations in regulator of G-protein signaling genes as susceptibility loci for second primary tumor/recurrence in head and neck squamous cell carcinoma. Carcinogenesis 31:1755-61
Zhang, Xiaofan; Yang, Hushan; Lee, J Jack et al. (2010) MicroRNA-related genetic variations as predictors for risk of second primary tumor and/or recurrence in patients with early-stage head and neck cancer. Carcinogenesis 31:2118-23
Wu, Xifeng; Spitz, Margaret R; Lee, J Jack et al. (2009) Novel susceptibility loci for second primary tumors/recurrence in head and neck cancer patients: large-scale evaluation of genetic variants. Cancer Prev Res (Phila) 2:617-24
William Jr, William N; Lee, J Jack; Lippman, Scott M et al. (2009) High-dose fenretinide in oral leukoplakia. Cancer Prev Res (Phila) 2:22-6
Papadimitrakopoulou, Vassiliki A; Lee, J Jack; William Jr, William N et al. (2009) Randomized trial of 13-cis retinoic acid compared with retinyl palmitate with or without beta-carotene in oral premalignancy. J Clin Oncol 27:599-604
Kawaguchi, Hidetoshi; El-Naggar, Adel K; Papadimitrakopoulou, Vali et al. (2008) Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancy. J Clin Oncol 26:354-60
Wu, Xifeng; Gu, Jian; Dong, Qiong et al. (2006) Joint effect of mutagen sensitivity and insulin-like growth factors in predicting the risk of developing secondary primary tumors and tumor recurrence in patients with head and neck cancer. Clin Cancer Res 12:7194-201
Lippman, Scott M; Lee, J Jack (2006) Reducing the ""risk"" of chemoprevention: defining and targeting high risk--2005 AACR Cancer Research and Prevention Foundation Award Lecture. Cancer Res 66:2893-903

Showing the most recent 10 out of 91 publications